Responsiveness of observer rating scales by analysis of number of days until improvement in patients with major depression

被引:4
作者
Lauge, N [1 ]
Behnke, K [1 ]
Sogaard, J [1 ]
Bahr, B [1 ]
Bech, P [1 ]
机构
[1] Frederiksborg Cent Cty Hosp, Psychiat Res Unit, DK-3400 Hillerod, Denmark
关键词
responsiveness; citalopram; mianserin; Hamilton Depression Scale (HAM-D); Montgomery-Asberg Scale (MADRS); Major Depression Rating Scale (MDS); Melancholia Scale (MES); Inventory for Depressive Symptomatology (IDS);
D O I
10.1016/S0924-9338(98)80138-7
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Several well-known observer scales, including the Hamilton Depression Scale (HAM-D), Montgomery-Asberg Scale (MADRS), Major Depression Raring Scale (MDS), Melancholia Scale (MES), and Inventory for Depressive Symptomatology (IDS) used for measuring severity of depressive states have been compared by their responsiveness in an open trial including patients treated with a combination of citalopram and mianserin. The patients fulfilled the Diagnostic and Statistical Manual (DSM)-IV criteria for major depressive episode, and all scored 18 or more on the KAM-D before treatment. Onset of antidepressant action was defined as an improvement of rating scale scores of 25% or more of pre-treatment scores. A response to treatment was defined as a reduction of 50% or more on the pre-treatment scores. The results showed that the number of treatment days until improvement was 11 to 13 with no difference between the scales. The days until response were between 18 and 21 with no difference between the scales. In conclusion, the depression scales were found to be equal in their ability to detect changes in depressive symptoms during treatment. The mean of days to response was 19 for the combination of citalopram and mianserin. This is similar to the response for the combination of fluoxetine and pinolol. (C) 1998 Elsevier, Paris.
引用
收藏
页码:143 / 145
页数:3
相关论文
共 18 条
[1]  
ARTIGAS F, 1996, AM J PSYCHIAT, V154, P37
[2]  
BECH P, 1993, J CLIN PSYCHIAT, V54, P18
[3]   The major depression rating scale (MDS). Inter-rater reliability and validity across different settings in randomized moclobemide trials [J].
Bech, P ;
Stage, KB ;
Nair, NPV ;
Larsen, JK ;
KraghSorensen, P ;
Gjerris, A .
JOURNAL OF AFFECTIVE DISORDERS, 1997, 42 (01) :39-48
[4]  
BECH P, 1989, NEW ANTIDEPRESSANTS, P56
[5]  
Bech P., 1996, The Bech, Hamilton and Zung Scales for Mood Disorders: Screening and Listening, V2nd, DOI [10.1007/978-3-642-61169-8, DOI 10.1007/978-3-642-61169-8]
[6]   Morning fluoxetine plus evening mianserin versus morning fluoxetine plus evening placebo in the acute treatment of major depression [J].
Dam, J ;
Ryde, L ;
Svejso, J ;
Lauge, N ;
Lauritsen, B ;
Bech, P .
PHARMACOPSYCHIATRY, 1998, 31 (02) :48-54
[7]  
DERIVAN A, 1995, PSYCHOPHARMACOL BULL, V31, P439
[8]   COMBINED TREATMENT WITH IMIPRAMINE AND MIANSERIN - A CONTROLLED PILOT-STUDY [J].
LAURITZEN, L ;
CLEMMESEN, L ;
KLYSNER, R ;
LOLDRUP, D ;
LUNDE, M ;
SCHAUMBURG, E ;
WAARST, S ;
BECH, P .
PHARMACOPSYCHIATRY, 1992, 25 (04) :182-186
[9]  
LYDIARD RB, 1984, PSYCHOPHARMACOL BULL, V20, P258
[10]   NEW DEPRESSION SCALE DESIGNED TO BE SENSITIVE TO CHANGE [J].
MONTGOMERY, SA ;
ASBERG, M .
BRITISH JOURNAL OF PSYCHIATRY, 1979, 134 (APR) :382-389